Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy
AbstractAllergen exposure chambers (AECs) have been developed for controlled allergen challenges of allergic patients mimicking natural exposure. As such, these facilities have been utilized e.g., for proof of concept, dose finding or the demonstration of onset of action and treatment effect sizes of antiallergic medication. Moreover, clinical effects of and immunological mechanisms in allergen immunotherapy (AIT) have been investigated in AECs. In Europe AIT products have to fulfill regulatory requirements for obtaining market authorization through Phase I to III clinical trials. Multiple Phase II (dose-range-finding or p...
Source: Clinical and Translational Allergy - July 28, 2020 Category: Allergy & Immunology Source Type: research
AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer —a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)
AbstractElevated serum IgE levels are associated with allergic disorders, parasitosis and specific immunologic abnormalities. In addition, epidemiological and mechanistic evidence indicates an association between IgE-mediated immune surveillance and protection from tumour growth. Intriguingly, recent studies reveal a correlation between IgE deficiency and increased malignancy risk. This is the first review discussing IgE levels and links to pathological conditions, with special focus on the potential clinical significance of ultra-low serum IgE levels and risk of malignancy. In this Position Paper we discuss: (a) the utili...
Source: Clinical and Translational Allergy - July 16, 2020 Category: Allergy & Immunology Source Type: research
Eustachian tube dysfunction in patients with house dust mite-allergic rhinitis
ConclusionsAR patients, especially those with severe nasal obstruction, could have ETD. The local conditions of the pharyngeal orifices of the eustachian tubes are closely related to the symptoms of ETD. After treatment with nasal glucocorticoids and oral antihistamines, eustachian tube function can significantly improve as nasal symptoms subside.Trial registration Chinese Clinical Trial Registery (ChiCTR2000029071) Registered 12 January 2020 —Retrospectively registered,http://www.chictr.org.cn/edit.aspx?pid=48328&htm=4 (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - July 14, 2020 Category: Allergy & Immunology Source Type: research
Citrullinated histone H3, a marker of extracellular trap formation, is increased in blood of stable asthma patients
ConclusionsAsthma is characterized by increased circulating H3cit likely related to the enhanced lung ETs formation. Inhibition of ETs might be a therapeutic option in selected asthma phenotypes, such as neutrophilic asthma. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - July 12, 2020 Category: Allergy & Immunology Source Type: research
Respiratory diseases and allergy in farmers working with livestock: a EAACI position paper
AbstractFarmers constitute a large professional group worldwide. In developed countries farms tend to become larger, with a concentration of farm operations. Animal farming has been associated with negative respiratory effects such as work-related asthma and rhinitis. However, being born and raised or working on a farm reduces the risk of atopic asthma and rhinitis later in life. A risk of chronic bronchitis and bronchial obstruction/COPD has been reported in confinement buildings and livestock farmers. This position paper reviews the literature linking exposure information to intensive animal farming and the risk of work-...
Source: Clinical and Translational Allergy - July 5, 2020 Category: Allergy & Immunology Source Type: research
Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma
ConclusionsPatients with CRSwNP + AS have distinct type 2-high inflammation-associated molecular signatures in nasal tissues compared to patients with CRSwNP-alone. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - July 2, 2020 Category: Allergy & Immunology Source Type: research
The disease burden in patients with respiratory allergies induced by house dust mites: a year-long observational survey in three European countries
ConclusionsIn a 13-month, fortnightly survey of patients in France, Italy and Spain with a self-reported history of moderate-to-severe, poorly controlled, HDM-induced allergic rhinitis and asthma, we found that a relevant minority of participants regularly reported a severe or very severe impact of their allergy on tiredness, sleep and professional activities (including time off work). The disease burden peaked in autumn and late spring. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - June 30, 2020 Category: Allergy & Immunology Source Type: research
Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation – summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019
AbstractConcerning development of medicinal products, children belong to a so-called “special population” for which additional legislation applies: Regulation (EC) No 1901/2006 on medicinal products for paediatric use sets up a system of requirements, rewards and incentives to ensure that medicinal products are researched, developed and authorized to meet the therapeutic needs o f children. Allergen Immunotherapy (AIT) is believed to contain a strong potential for immunomodulatory effects inducing sustained clinical efficacy after cessation of treatment (disease modifying effect) and thereby may prevent the progression...
Source: Clinical and Translational Allergy - June 28, 2020 Category: Allergy & Immunology Source Type: research
Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
ConclusionsIn an observational real-world setting, add-on omalizumab for severe allergic asthma was effective in improving asthma control, lung function and in reducing exacerbations, including in those patients with CRSwNP. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - June 25, 2020 Category: Allergy & Immunology Source Type: research
Digital transformation of health and care to sustain Planetary Health: The MASK proof-of-concept for airway diseases —POLLAR symposium under the auspices of Finland’s Presidency of the EU, 2019 and MACVIA-France, Global Alliance against Chronic Respiratory Diseases (GARD, WH0) demonstration project, Reference Site Collaborative Network of the European Innovation Partnership on Active and Healthy Ageing
AbstractIn December 2019, a conference entitled “Europe That Protects: Safeguarding Our Planet, Safeguarding Our Health” was held in Helsinki. It was co-organized by the Finnish Institute for Health and Welfare, the Finnish Environment Institute and the European Commission, under the auspices of Finland’s Presidency of the EU. As a side event, a symposium organized as the final POLLAR (Impact of air POLLution on Asthma and Rhinitis) meeting explored the digital transformation of health and care to sustain planetary health in airway diseases. The Finnish Allergy Programme collaborates with MASK (Mobile Airways Sen...
Source: Clinical and Translational Allergy - June 18, 2020 Category: Allergy & Immunology Source Type: research
Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model
ConclusionDuring COVID-19 pandemic, allergists have the responsibility of balancing individual patients ’ needs with public health issues, and innovative tools, such as telemedicine and digital medicine services, can be helpful to reduce the risk of viral spreading while delivering up-to-date personalized care. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - June 17, 2020 Category: Allergy & Immunology Source Type: research
Molecular approach to a patient ’s tailored diagnosis of the oral allergy syndrome
AbstractOral allergy syndrome (OAS) is one of the most common IgE-mediated allergic reactions. It is characterized by a number of symptoms induced by the exposure of the oral and pharyngeal mucosa to allergenic proteins belonging to class 1 or to class 2 food allergens. OAS occurring when patients sensitized to pollens are exposed to some fresh plant foods has been called pollen food allergy syndrome (PFAS). In the wake of PFAS, several different associations of allergenic sources have been progressively proposed and called syndromes. Molecular allergology has shown that these associations are based on IgE co-recognition t...
Source: Clinical and Translational Allergy - June 16, 2020 Category: Allergy & Immunology Source Type: research
Epinephrine delivery via EpiPen ® Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances
ConclusionsEpinephrine delivery via EpiPen resulted in greater early systemic exposure to epinephrine vs IM syringe as assessed by epinephrine plasma levels. Delivery via EpiPen was consistent across participants with a wide range of STMD, even when the needle may not have penetrated the muscle.Trial registrationsThis trial was registered with the German Clinical Trials Register (DRKS-ID: DRKS00011263; secondary ID, EudraCT 2016-000104-29) on 23 March 2017. (Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - June 9, 2020 Category: Allergy & Immunology Source Type: research
Pru p 3 oral immunotherapy efficacy, induced immunological changes and quality of life improvement in patients with LTP syndrome
(Source: Clinical and Translational Allergy)
Source: Clinical and Translational Allergy - June 7, 2020 Category: Allergy & Immunology Source Type: research
New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?
AbstractNew recommendations from the Global Initiative for Asthma (GINA) were released in a pocket guide form on April 12, 2019. These recommendations provide very important changes to the management of asthma, especially regarding the treatment of intermittent and mild asthma. Due to safety concerns, GINA experts no longer recommend treatment with a short-acting β2 agonist alone. Henceforth, all adults and adolescents (but not yet children) with mild asthma should receive either symptom-driven or daily low-dose ICS. The main goal of this new approach is to reduce the risk of serious asthma exacerbations and asthma-relate...
Source: Clinical and Translational Allergy - June 2, 2020 Category: Allergy & Immunology Source Type: research
